ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
AbbVie banishes the ghost of Stemcentrx
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Argenx’s efforts to Advance fall flat
Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
A reprieve for Blenrep?
Against the odds GSK’s Dreamm-7 study yields a positive survival readout.
ASH 2023 preview – Darzalex gets a first-line boost from Perseus
But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?
